Therapeutic targeting of metabolic interactions between cancer and immune cells to improve the graft-versus-leukemia effect

治疗靶向癌症和免疫细胞之间的代谢相互作用以改善移植物抗白血病效应

基本信息

  • 批准号:
    492259164
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    德国
  • 项目类别:
    WBP Fellowship
  • 财政年份:
    2021
  • 资助国家:
    德国
  • 起止时间:
    2020-12-31 至 2022-12-31
  • 项目状态:
    已结题

项目摘要

Acute myeloid leukemia (AML) is a malignant disease characterized by an uncontrolled proliferation of myeloblasts in the bone marrow leading to an aggressive clinical course in most patients. One potent curative treatment option for AML is allogeneic hematopoietic cell transplantation (allo-HCT), in which alloreactive T cells from a foreign donor eliminate residual leukemia cells. This process is termed graft-versus-leukemia effect (GVL). However, a significant percentage of allo-HCT recipients develop an AML relapse. AML relapse can be treated by administering donor lymphocyte infusions (DLI) in combination with cytotoxic drugs, but the success of this approach is limited. One possible mechanism that leads to immune evasion of AML cells is an altered metabolism resulting from selection pressure by the cytotoxic treatment and the donor immune system. Recognizing which metabolic pathways are employed by therapy-surviving AML cells could offer novel targets to strengthen the GVL effect.In preliminary experiments I observed that chemotherapy-resistant AML cells rewired their metabolism during recovery from cytotoxic stress. These cells accumulated several metabolites, including hexosamine biosynthesis pathway endpoint UDP-GlcNAc, which is essential for post-translational glycosylation of proteins, as well as the energy-rich metabolites creatine and phosphocreatine. Data from gene expression analysis and CRISPR-Cas9-induced deletion models suggested that increased abundance of creatine in the cells was due to elevated uptake from the microenvironment. Simultaneously, I found that T cells likewise accumulated creatine during effector function development and that deleting the creatine transporter SLC6A8 impaired T cell function by reducing cytokine production. In my project, I will focus on following aims: (i) to explore the impact of creatine metabolism in AML cells and T cells on the GVL effect; (ii) to test the potential of modulations in the hexosamine biosynthesis pathway and protein glycosylation for enhancement of the GVL effect; (iii) to determine the significance of oncogenic mutations and the type of AML treatment on metabolic competition between AML and T cells. I will achieve these objectives by using in vitro techniques and in vivo mouse models. The role of specific genes will be studied by CRISPR-Cas9-incuded knockdown and plasmid-mediated overexpression. Sample analysis will be performed by liquid-chromatography-mass spectrometry, RNA sequencing, flow cytometry and functional metabolic assays. The project will be supported by my host, Prof. Erika Pearce at the Johns Hopkins University School of Medicine, who will provide scientific expertise and the necessary technical equipment. This project aims to identify novel pharmacological strategies that target metabolic interactions between AML cells and T lymphocytes with the ultimate goal to boost the GVL effect and induce long-lasting AML remissions.
急性髓性白血病(AML)是一种恶性疾病,其特点是骨髓中成髓细胞增殖不受控制,导致大多数患者的临床病程具有侵袭性。同种异体造血细胞移植是治疗急性髓性白血病的一种有效的治疗选择,其中来自外源供体的同种异体反应性T细胞消除了残留的白血病细胞。这个过程被称为移植物抗白血病效应(GVL)。然而,很大比例的同种异体hct受体发生AML复发。AML复发可以通过供体淋巴细胞输注(DLI)联合细胞毒性药物治疗,但这种方法的成功是有限的。导致AML细胞免疫逃避的一种可能机制是细胞毒性治疗和供体免疫系统的选择压力导致的代谢改变。识别治疗存活的AML细胞所使用的代谢途径可以提供新的靶点来加强GVL的作用。在初步实验中,我观察到耐化疗的AML细胞在从细胞毒性应激中恢复的过程中重新连接了它们的代谢。这些细胞积累了几种代谢物,包括己糖胺生物合成途径终点UDP-GlcNAc,这是蛋白质翻译后糖基化所必需的,以及能量丰富的代谢物肌酸和磷酸肌酸。来自基因表达分析和crispr - cas9诱导缺失模型的数据表明,细胞中肌酸丰度的增加是由于微环境摄取增加所致。同时,我发现T细胞同样在效应功能发展过程中积累肌酸,删除肌酸转运体SLC6A8通过减少细胞因子的产生而损害T细胞功能。在我的项目中,我将重点关注以下目标:(I)探索AML细胞和T细胞中肌酸代谢对GVL效应的影响;(ii)测试调节己糖胺生物合成途径和蛋白质糖基化的潜力,以增强GVL的作用;(iii)确定致瘤突变和AML治疗类型对AML和T细胞之间代谢竞争的意义。我将通过使用体外技术和体内小鼠模型来实现这些目标。特定基因的作用将通过crispr - cas9包括敲低和质粒介导的过表达来研究。样品分析将通过液相色谱-质谱法、RNA测序、流式细胞术和功能代谢分析进行。我的东道主约翰霍普金斯大学医学院的Erika Pearce教授将支持这个项目,她将提供科学专门知识和必要的技术设备。该项目旨在确定针对AML细胞和T淋巴细胞之间代谢相互作用的新药理学策略,最终目标是增强GVL效应并诱导持久的AML缓解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Professorin Dr. Petya Apostolova其他文献

Professorin Dr. Petya Apostolova的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

靶向PARylation介导的DNA损伤修复途径在恶性肿瘤治疗中的作用与分子机制研究
  • 批准号:
    82373145
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
诱导性多能干细胞rDNA区基因打靶在线粒体视神经病中的治疗研究
  • 批准号:
    81970829
  • 批准年份:
    2019
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
Pre-targeting/Click反应介导的自体循环干细胞在心脏缺血损伤修复中的应用及机制研究
  • 批准号:
    81873493
  • 批准年份:
    2018
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
以IGF2/IGF1R与SYT/SSX1为靶点治疗滑膜肉瘤的实验研究
  • 批准号:
    81102033
  • 批准年份:
    2011
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
基于ZFN/phiC31系统的新型基因打靶技术的建立(果蝇)
  • 批准号:
    31171278
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Therapeutic targeting of SIRT3 for aggressive and refractory lymphomas
SIRT3 治疗侵袭性和难治性淋巴瘤的靶向治疗
  • 批准号:
    10587454
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Enolase inhibitors as therapeutic leads for Naegleria fowleri infections
烯醇酶抑制剂作为福氏耐格里阿米巴感染的治疗先导药物
  • 批准号:
    10739388
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Overcoming racial health disparities in lung cancer through innovative mechanism-based therapeutic strategies
通过基于机制的创新治疗策略克服肺癌的种族健康差异
  • 批准号:
    10660294
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Targeting Metabolic Vulnerabilities with Synergistic Therapeutic Agents for Treatment of Metastatic Castration-Resistant Prostate Cancer.
用协同治疗剂针对代谢脆弱性治疗转移性去势抵抗性前列腺癌。
  • 批准号:
    10677412
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Therapeutic Agents Targeting Cryptococcal Infections
针对隐球菌感染的治疗药物
  • 批准号:
    10697960
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Developing a programmable siRNA-based therapeutic platform for gene silencing in the skin
开发基于 siRNA 的可编程治疗平台,用于皮肤基因沉默
  • 批准号:
    10723917
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis
开发一种针对糖基磷脂酰肌醇 (GPI) 生物合成和细胞壁生物合成的新型广谱抗真菌治疗药物
  • 批准号:
    10759723
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Exploiting alpha-ketoglutarate-dependent metabolism for therapeutic benefit in acute myeloid leukemia
利用α-酮戊二酸依赖性代谢来治疗急性髓系白血病
  • 批准号:
    10684842
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Evaluating the therapeutic potential of vagal CART circuitry for treating metabolic disease
评估迷走神经 CART 回路治疗代谢疾病的治疗潜力
  • 批准号:
    10341154
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML
治疗靶向 p53 重新激活诱导的 OXPHOS 依赖性和应激反应,以克服 AML 中对 Venetoclax/HMA 的耐药性
  • 批准号:
    10356325
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了